MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does FDA Clearance Mean for AI-Powered Diagnostics

1 week ago

What Does Teva's Recent FDA Acceptance Mean for Investors

2 months ago

What Does the FDA Warning Mean for Medline's Operations

1 months ago

What Does the FDA's NDA Acceptance Mean for Mineralys Therapeutics

1 week ago

Precigen: Full Commercial Validation And Room To Run

Precigen projects reaching cash flow positive status in 2024, supported by the early FDA approval and rapid adoption of its PAPZIMEOS therapy. The company is targeting a $2B global market for the trea...

PGEN

Stock News•1 week ago

Rare disease families find roadmap to drug development at bootcamps

Rare disease families are increasingly leading drug development research for their children. Ultragenyx’s Rare Bootcamp provides these advocates with a structured roadmap to navigate the complex clini...

RARE

Stock News•1 week ago

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (RARE) released its Q1 2026 earnings results via transcript. The report details the company's financial performance and operational progress for the first quarter of the...

RARE

Stock News•2 weeks ago

US FDA approves Axsome's drug for Alzheimer's-related agitation

The U.S. FDA approved Axsome Therapeutics' drug for treating agitation in Alzheimer's disease patients. This regulatory clearance marks a significant milestone for the company's portfolio, potentially...

AXSM